Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection

Abstract We previously demonstrated that pretreatment quantitative anti–hepatitis B core protein (qAnti-HBc) levels can predict the treatment response for both interferon and nucleoside analogue therapy, but the characteristics of qAnti-HBc during chronic hepatitis B virus (HBV) infection remain poorly understood. To understand this issue, the qAnti-HBc levels were evaluated in individuals with past HBV infection, occult HBV infection and chronic HBV infection in the immune tolerance phase, immune clearance phase, low-replicative phase and hepatitis B e antigen (HBeAg)-negative hepatitis phase. Individuals with hepatitis B surface antigen ( n  = 598, 3.74 ± 0.90 log 10 IU/mL) had significantly higher (p  R  = 0.663, p